Breast cancers which lack expression of the estrogen receptor (ER), The cancer-immunity cycle is a complex, multi-step, self-propagating cycle, which allows for the identification and eradication of cancer cells through the induction and amplification of T-cell responses. Key steps in the process include:
Breast cancers which lack expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)-so-called triple-negative breast cancers (TNBC)-make up 15-20% of the more than 230,000 cases of breast cancer diagnosed in the US each year. 1 Metastatic TNBC remains an important clinical challenge as it is associated with a median survival of under 12 months. While breast cancer has not historically been thought of as an immunogenic tumor, there have been a number of observations made over the past decade that have provided the rationale for investigating immunotherapy as a viable therapeutic option for TNBC.
Loi and colleagues have observed that ER-negative breast cancers have a higher density of tumor infiltrating lymphocytes (TILs) than their ER-positive counterparts. 2 The ability to profile breast tumors on a molecular level has led to two key observations: first, that programmed death ligand 1 (PD-L1) gene expression is significantly greater in TNBCs compared with non-TNBCs, 3 and second, that a subset of TNBC tumors-the immunomodulatory subtype-is characterized by elevated expression of genes involved in T-cell function. 4 Furthermore, TNBCs are genomically unstable and have high rates of genetic mutations, which can in turn lead to neo-antigen presentation and induction of an immune response through activation of the cancer-immunity cycle. 5, 6 The cancer-immunity cycle is a complex, multi-step, self-propagating cycle, which allows for the identification and eradication of cancer cells through the induction and amplification of T-cell responses. Key steps in the process include:
• release of cancer cell antigens;
• presentation of these antigens by antigen presenting cells;
• priming and activation of the T-cell response;
• trafficking of T-cells to tumors;
• infiltration of the tumor by T-cells;
• T-cell recognition of cancer cells; and
• cancer cell death, which in turn leads to antigen release (step 1), and propagation of the cycle.
Each step of this cycle is tightly regulated by both stimulatory and inhibitory factors, which lead to a delicate balance between immunity and unrestrained autoimmunity. were heavily pre-treated, with 89% of patients having been exposed to ≥4 systemic therapies. Similar to the pembrolizumab study, treatmentrelated adverse events were common, with 63% of patients experiencing a treatment-related AE of any grade. These were typically grade 1-2 and were easily managed, with the most common AEs including fatigue, nausea, and pyrexia. Eleven per cent of patients were found to have grade 3 treatment-related AE, and two deaths were reported and under further investigation at the time of presentation. 9 Of the 21 patients considered evaluable for efficacy, the ORR was 19%, which included two CRs and two PRs. Responses were durable, with a median duration of response not yet reached at the time of presentation (range 18-56+ weeks). 9 Blockade of the PD-1/PD-L1 axis has now been studied in two phase I clinical trials in TNBC and has resulted in promising, durable responses.
In addition, treatment with these immune checkpoint agents appeared safe and tolerable, with the majority of side effects being mild and easily managed. Immunotherapy has arrived as an important tool in the fight against cancer, and will likely be an important treatment option for TNBC.
Tumors evolve to evade the immune system in different ways and at different steps in the cancer-immunity cycle, and immune checkpoint- 
